Mark Udall actually said...

I do understand, Mr. Blum, that if the IPAB recommendations are not acceptable to the Congress, we can simply override them with our own ide...

Again, the point of the hearing is how do we maintain quality, how do we encourage the pharmaceutical sector to innovate and take some risks...

The Affordable Care Act was focused in part on outcomes.

And that's the point of the hearing today, and I want to thank Senator Kohl and Senator Corker for convening this.